Cargando…
Targeting Metabolic Modulation and Mitochondrial Dysfunction in the Treatment of Heart Failure
Despite significant improvements in morbidity and mortality with current evidence-based pharmaceutical-based treatment of heart failure (HF) over the previous decades, the burden of HF remains high. An alternative approach is currently being developed, which targets myocardial energy efficiency and...
Autores principales: | Steggall, Abbey, Mordi, Ify R., Lang, Chim C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547981/ https://www.ncbi.nlm.nih.gov/pubmed/28933367 http://dx.doi.org/10.3390/diseases5020014 |
Ejemplares similares
-
Inflammation as a therapeutic target in heart failure with preserved ejection fraction
por: Peh, Zhen Hui, et al.
Publicado: (2023) -
Type 2 Diabetes, Metabolic Traits, and Risk of Heart Failure: A Mendelian Randomization Study
por: Mordi, Ify R., et al.
Publicado: (2021) -
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
por: Mordi, Natalie A., et al.
Publicado: (2020) -
Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
por: Mordi, Ify R., et al.
Publicado: (2020) -
Precision Medicine and Adverse Drug Reactions Related to Cardiovascular Drugs †
por: Noyes, James D., et al.
Publicado: (2021)